Literature DB >> 8670758

Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits.

K C Cundy1, G Lynch, J P Shaw, M J Hitchcock, W A Lee.   

Abstract

PURPOSE: This study was designed to evaluate the intraocular distribution and metabolism of the antiviral nucleotide analogs cidofovir and cyclic 1-[(S)-3-hydroxy-2-(phosphonomethoxy) propyl]cytosine (HPMPC) in New Zealand white rabbits following intravitreal administration.
METHODS: Male rabbits received either 14C-cidofovir or 14C-cyclic HPMPC by intravitreal injection into both eyes (50 micrograms/eye, 11 microCi/eye). Two animals per group were sacrificed at 24, 48, 72 or 240 h post-dose. Ocular tissues, kidney and liver were oxidized to determine total radioactivity and metabolites were determined by HPLC.
RESULTS: At 24 h post-dose, total radioactivity was 9.96 and 5.18 micrograms-equiv/g for cidofovir and cyclic HPMPC, respectively, in vitreous and 20.9 and 3.54 micrograms-equiv/g, respectively, in retina. Although the initial vitreal clearance was 2-fold faster for the cyclic analog, the estimated terminal elimination half-lives in vitreous (42 hr) and in retina (66-77 hr) were similar for both drugs. By 240 h post-dose, radioactivity in all ocular tissues was approximately ten-fold higher for cidofovir. Radioactivity in vitreous at 240 h after intravitreal dosing with either drug contained cidofovir, cyclic HPMPC and cidofovir-phosphocholine.
CONCLUSIONS: The long retinal half-life observed presumably reflects formation of phosphorylated cidofovir within retinal cells. Cidofovir achieved a ten-fold higher level of phosphorylated drug in retina than cyclic HPMPC: Therefore, intravitreal cidofovir may be expected to suppress progression of retinitis for a longer period than an equivalent intravitreal dose of cyclic HPMPC: The intravitreal half-life of cidofovir was 20-fold longer than that of ganciclovir in the same animal model.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8670758     DOI: 10.3109/02713689609000768

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  9 in total

1.  Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.

Authors:  Fernando J Bravo; David I Bernstein; James R Beadle; Karl Y Hostetler; Rhonda D Cardin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Retina-choroid-sclera permeability for ophthalmic drugs in the vitreous to blood direction: quantitative assessment.

Authors:  Nahid Haghjou; Mohammad J Abdekhodaie; Yu-Ling Cheng
Journal:  Pharm Res       Date:  2012-10-02       Impact factor: 4.200

3.  Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug.

Authors:  Haiyan Wang; Jay Chhablani; William R Freeman; James R Beadle; Karl Y Hostetler; Kathrin Hartmann; Laura Conner; Kathy A Aldern; Lindsey Pearson; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-12-09       Impact factor: 4.799

Review 4.  Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.

Authors:  K C Cundy
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

5.  Intraocular pharmacokinetics of a crystalline lipid prodrug, octadecyloxyethyl-cyclic-cidofovir, for cytomegalovirus retinitis.

Authors:  Lingyun Cheng; James R Beadle; Ajay Tammewar; Karl Y Hostetler; Carl Hoh; William R Freeman
Journal:  J Ocul Pharmacol Ther       Date:  2011-02-25       Impact factor: 2.671

6.  Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir.

Authors:  Lingyun Cheng; Karl Y Hostetler; Jeffery Lee; Hyoung Jun Koh; James R Beadle; Kenichiro Bessho; Mitsuko Toyoguchi; Kathy Aldern; Jean-Marc Bovet; William R Freeman
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-11       Impact factor: 4.799

7.  Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.

Authors:  Feiyan Ma; Kaihui Nan; SuNa Lee; James R Beadle; Huiyuan Hou; William R Freeman; Karl Y Hostetler; Lingyun Cheng
Journal:  Eur J Pharm Biopharm       Date:  2014-12-13       Impact factor: 5.571

8.  Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR).

Authors:  Chandrasekar Durairaj; Jaymin C Shah; Shruti Senapati; Uday B Kompella
Journal:  Pharm Res       Date:  2008-10-08       Impact factor: 4.200

Review 9.  Peptidomimetics Therapeutics for Retinal Disease.

Authors:  Dylan E Parsons; Soo Hyeon Lee; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Mark Smith; Vinit B Mahajan
Journal:  Biomolecules       Date:  2021-02-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.